{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:09:17Z","timestamp":1784128157701,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,21]]},"DOI":"10.7759\/cureus.99794","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T03:54:10Z","timestamp":1766375650000},"source":"Crossref","is-referenced-by-count":1,"title":["Patterns of Bruton\u2019s Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study"],"prefix":"10.7759","author":[{"given":"Azra","family":"Naseem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amullya","family":"Pednekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective","volume":"175","author":"Satterthwaite AB","year":"2000","unstructured":"Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000, 175:120-7.","journal-title":"Immunol Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger JA","year":"2018","unstructured":"Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018, 18:148-67. 10.1038\/nrc.2017.121","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00864-9","article-title":"Correction to: Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features","volume":"17","author":"Shirley M","year":"2022","unstructured":"Shirley M. Correction to: Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features. Target Oncol. 2022, 17:93. 10.1007\/s11523-021-00864-9","journal-title":"Target Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks RW","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014, 14:219-32. 10.1038\/nrc3702","journal-title":"Nat Rev Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton's tyrosine kinase in CLL","volume":"12","author":"Ahn IE","year":"2021","unstructured":"Ahn IE, Brown JR. Targeting Bruton's tyrosine kinase in CLL. Front Immunol. 2021, 12:687458. 10.3389\/fimmu.2021.687458","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063234","article-title":"Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms","volume":"25","author":"Mouhssine S","year":"2024","unstructured":"Mouhssine S, Maher N, Matti BF, Alwan AF, Gaidano G. Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms. Int J Mol Sci. 2024, 25:3234. 10.3390\/ijms25063234","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00315-9","article-title":"Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect","volume":"11","author":"Wang H","year":"2022","unstructured":"Wang H, Guo H, Yang J, Liu Y, Liu X, Zhang Q, Zhou K. Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect. Exp Hematol Oncol. 2022, 11:60. 10.1186\/s40164-022-00315-9","journal-title":"Exp Hematol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: Ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro RA","year":"2015","unstructured":"de Claro RA, McGinn KM, Verdun N, et al.. FDA approval: Ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015, 21:3586-90. 10.1158\/1078-0432.CCR-14-2225","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S73559","article-title":"A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia","volume":"11","author":"Tucker DL","year":"2015","unstructured":"Tucker DL, Rule SA. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Ther Clin Risk Manag. 2015, 11:979-90. 10.2147\/TCRM.S73559","journal-title":"Ther Clin Risk Manag"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon SP","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, et al.. Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia. N Engl J Med. 2015, 372:1430-40. 10.1056\/NEJMoa1501548","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy A","year":"2020","unstructured":"Noy A, de Vos S, Coleman M, et al.. Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020, 4:5773-84. 10.1182\/bloodadvances.2020003121","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000418","article-title":"Recall of ibrutinib and issues with therapeutic approval","volume":"3","author":"Lipfert C","year":"2024","unstructured":"Lipfert C, Kim MS, Haslam A, Prasad VK. Recall of ibrutinib and issues with therapeutic approval. BMJ Oncol. 2024, 3:000418. 10.1136\/bmjonc-2024-000418","journal-title":"BMJ Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam C","year":"2024","unstructured":"Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024, 8:2300-9. 10.1182\/bloodadvances.2023012221","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1413985","article-title":"Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"15","author":"Ke L","year":"2024","unstructured":"Ke L, Li S, Huang D, Wang Y. Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis. Front Pharmacol. 2024, 15:1413985. 10.3389\/fphar.2024.1413985","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290872","article-title":"Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib","volume":"18","author":"Lin DY","year":"2023","unstructured":"Lin DY, Andreotti AH. Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib. PLoS One. 2023, 18:0290872. 10.1371\/journal.pone.0290872","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01414","article-title":"Second-generation Bruton\u2019s tyrosine kinase inhibitors: simply the best treatments for chronic lymphocytic leukemia?","volume":"39","author":"Stephens DM","year":"2021","unstructured":"Stephens DM. Second-generation Bruton\u2019s tyrosine kinase inhibitors: simply the best treatments for chronic lymphocytic leukemia?. J Clin Oncol. 2021, 39:3419-22. 10.1200\/JCO.21.01414","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al.. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021, 39:3441-52. 10.1200\/JCO.21.01210","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134280","article-title":"Efficacy and safety of zanubrutinib in patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): follow-up results from Arm C of the Sequoia (BGB-3111-304) trial","volume":"136","author":"Brown JR","year":"2020","unstructured":"Brown JR, Robak T, Ghia P, et al.. Efficacy and safety of zanubrutinib in patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): follow-up results from Arm C of the Sequoia (BGB-3111-304) trial. Blood. 2020, 136:11-2. 10.1182\/blood-2020-134280","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020240","article-title":"Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders","volume":"141","author":"Thompson PA","year":"2023","unstructured":"Thompson PA, Tam CS. Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood. 2023, 141:3137-42. 10.1182\/blood.2023020240","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080764","article-title":"Non-covalent BTK inhibitors-the new btkids on the block for B-cell malignancies","volume":"11","author":"Lewis KL","year":"2021","unstructured":"Lewis KL, Cheah CY. Non-covalent BTK inhibitors-the new btkids on the block for B-cell malignancies. J Pers Med. 2021, 11:764. 10.3390\/jpm11080764","journal-title":"J Pers Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1629465","article-title":"EUROCOVER CLL: reimbursement and accessibility of new treatments in relapsed\/refractory chronic lymphocytic leukemia","volume":"16","author":"Monica M","year":"2025","unstructured":"Monica M, Becirovic S, Bianchi-Manaila I, et al.. EUROCOVER CLL: reimbursement and accessibility of new treatments in relapsed\/refractory chronic lymphocytic leukemia. Front. Pharmacol. 2025, 16:1629465. 10.3389\/fphar.2025.1629465","journal-title":"Front. Pharmacol"},{"key":"ref22","unstructured":"Newer therapy drugs for cancer treatment are not cost-effective, finds PGI-AIIMS study. (2023). Accessed. September 7, 2025: https:\/\/timesofindia.indiatimes.com\/city\/chandigarh\/newer-therapy-drugs-for-cancer-treatment-are-not-cost-effective-f...."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2023.100201","article-title":"Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India","volume":"2","author":"Nehra P","year":"2023","unstructured":"Nehra P, Chauhan AS, Malhotra P, et al.. Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India. Lancet Reg Health Southeast Asia. 2023, 2:100201. 10.1016\/j.lansea.2023.100201","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00032","article-title":"Chronic lymphocytic leukemia: real-world data from India","volume":"6","author":"Tejaswi V","year":"2020","unstructured":"Tejaswi V, Lad DP, Jindal N, et al.. Chronic lymphocytic leukemia: real-world data from India. JCO Glob Oncol. 2020, 6:866-72. 10.1200\/GO.20.00032","journal-title":"JCO Glob Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000488","article-title":"Addressing the affordability gap of novel cancer treatments in developing countries","volume":"3","author":"Miyasato G","year":"2024","unstructured":"Miyasato G, Shah C, Gorsuch T, Venkateswaran R, Kasivajjala VC, Misra M. Addressing the affordability gap of novel cancer treatments in developing countries. PLOS Digit Health. 2024, 3:0000488. 10.1371\/journal.pdig.0000488","journal-title":"PLOS Digit Health"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922370","article-title":"Editorial: real world outcomes of lymphoma from India","volume":"12","author":"Kumar L","year":"2022","unstructured":"Kumar L, Kn N, Gujral S, Kulkarni P, Stockler MR, Nair R. Editorial: real world outcomes of lymphoma from India. Front Oncol. 2022, 12:922370. 10.3389\/fonc.2022.922370","journal-title":"Front Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12938-021-00973-6","article-title":"The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019","volume":"21","author":"Yao Y","year":"2022","unstructured":"Yao Y, Lin X, Li F, Jin J, Wang H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022, 21:4. 10.1186\/s12938-021-00973-6","journal-title":"Biomed Eng Online"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project","volume":"101","author":"Perry AM","year":"2016","unstructured":"Perry AM, Diebold J, Nathwani BN, et al.. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016, 101:1244-50. 10.3324\/haematol.2016.148809","journal-title":"Haematologica"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.125235","article-title":"Malignant lymphoma in Eastern India: a retrospective analysis of 455 cases according to World Health Organization classification","volume":"34","author":"Mondal SK","year":"2013","unstructured":"Mondal SK, Mandal PK, Samanta TK, Chakaborty S, Roy SD, Roy S. Malignant lymphoma in Eastern India: a retrospective analysis of 455 cases according to World Health Organization classification. Indian J Med Paediatr Oncol. 2013, 34:242-6. 10.4103\/0971-5851.125235","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.25259\/IJMIO_18_2023","article-title":"Spectrum of lymphomas in India","volume":"9","author":"Sarma S","year":"2024","unstructured":"Sarma S, Mehta J. Spectrum of lymphomas in India. Int J Mol and ImmuOncol. 2024, 9:16-24. 10.25259\/IJMIO_18_2023","journal-title":"Int J Mol and ImmuOncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-020-01382-w","article-title":"Waldenstr\u00f6m macroglobulinemia: clinico-pathological profile and treatment outcomes of patients from a tertiary care centre of North India","volume":"37","author":"Kumar S","year":"2021","unstructured":"Kumar S, Sanjeev, Rahman K, et al.. Waldenstr\u00f6m macroglobulinemia: clinico-pathological profile and treatment outcomes of patients from a tertiary care centre of North India. Indian J Hematol Blood Transfus. 2021, 37:386-90. 10.1007\/s12288-020-01382-w","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref32","article-title":"Diffuse large B-cell lymphoma","author":"Padala SA","year":"2025","unstructured":"Padala SA, Kallam A. Diffuse large B-cell lymphoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref33","article-title":"Chronic lymphocytic leukemia","author":"Mukkamalla SKR","year":"2025","unstructured":"Mukkamalla SKR, Taneja A, Malipeddi D, Master SR. Chronic lymphocytic leukemia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref34","article-title":"Follicular lymphoma","author":"Kaseb H","year":"2025","unstructured":"Kaseb H, Ali MA, Gasalberti DP, Koshy NV. Follicular lymphoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref35","article-title":"Mantle cell lymphoma","author":"Lynch DT","year":"2025","unstructured":"Lynch DT, Koya S, Dogga S, Kumar A. Mantle cell lymphoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.183","article-title":"Extranodal and splenic small B-cell lymphoma","volume":"26","author":"Wotherspoon AC","year":"2013","unstructured":"Wotherspoon AC. Extranodal and splenic small B-cell lymphoma. Mod Pathol. 2013, 26:29-41. 10.1038\/modpathol.2012.183","journal-title":"Mod Pathol"},{"key":"ref37","unstructured":"Hyperviscosity syndrome. (2025). Accessed. September 13, 2025: https:\/\/www.acep.org\/criticalcare\/newsroom\/newsroom-articles\/january-2025\/hyperviscosity-syndrome."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v13i5.6529","article-title":"Beyond guidelines: real world treatment & outcomes of chronic lymphocytic leukemia at a tertiary Indian Cancer Centre","volume":"13","author":"Jacob LA","year":"2025","unstructured":"Jacob LA, Koshy BE, Kukunuri S. Beyond guidelines: real world treatment & outcomes of chronic lymphocytic leukemia at a tertiary Indian Cancer Centre. Med Res Arch. 2025, 13:10.18103\/mra.v13i5.6529","journal-title":"Med Res Arch"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.05.005","article-title":"Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods","volume":"42","author":"Chauffaille ML","year":"2020","unstructured":"Chauffaille ML, Zalcberg I, Barreto WG, Bendit I. Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods. Hematol Transfus Cell Ther. 2020, 42:261-8. 10.1016\/j.htct.2020.05.005","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2024.10.018","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)","volume":"164","author":"Medina \u00c1","year":"2025","unstructured":"Medina \u00c1, Munta\u00f1ola A, Crespo M, et al.. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC). Med Clin (Barc). 2025, 164:305-305.e17. 10.1016\/j.medcli.2024.10.018","journal-title":"Med Clin (Barc)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01007-2","article-title":"Expert consensus on the management of chronic lymphocytic leukaemia in Asia","volume":"23","author":"Tse E","year":"2023","unstructured":"Tse E, Kwong YL, Goh YT, et al.. Expert consensus on the management of chronic lymphocytic leukaemia in Asia. Clin Exp Med. 2023, 23:2895-907. 10.1007\/s10238-023-01007-2","journal-title":"Clin Exp Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01732-9","article-title":"Managing Waldenstr\u00f6m's macroglobulinemia with BTK inhibitors","volume":"37","author":"Buske C","year":"2023","unstructured":"Buske C, Jurczak W, Salem JE, Dimopoulos MA. Managing Waldenstr\u00f6m's macroglobulinemia with BTK inhibitors. Leukemia. 2023, 37:35-46. 10.1038\/s41375-022-01732-9","journal-title":"Leukemia"},{"key":"ref43","unstructured":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma. (2025). Accessed. September 13, 2025: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1478."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007247","article-title":"Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma","volume":"6","author":"Narkhede M","year":"2022","unstructured":"Narkhede M, Goyal G, Shea L, Mehta A, Giri S. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022, 6:4122-31. 10.1182\/bloodadvances.2022007247","journal-title":"Blood Adv"},{"key":"ref45","unstructured":"Glenmark Pharmaceuticals to launch DCGI-approved Brukinsa\u00ae in India to advance treatment of hematological malignancies. (2025). Accessed. September 13, 2025: https:\/\/firstwordpharma.com\/story\/5970570."},{"key":"ref46","unstructured":"FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma. (2024). Accessed. September 13, 2025: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-relapsed-...."},{"key":"ref47","unstructured":"FDA grants accelerated approval to zanubrutinib for marginal zone lymphoma. (2024). Accessed. September 13, 2025: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-marginal-...."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst B","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, et al.. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024, 35:762-8. 10.1016\/j.annonc.2024.06.016","journal-title":"Ann Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009739","article-title":"Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia","volume":"7","author":"Roeker LE","year":"2023","unstructured":"Roeker LE, DerSarkissian M, Ryan K, et al.. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Adv. 2023, 7:4291-301. 10.1182\/bloodadvances.2023009739","journal-title":"Blood Adv"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00012","article-title":"Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between India and the United States","volume":"6","author":"Sathyanarayanan V","year":"2020","unstructured":"Sathyanarayanan V, Flowers CR, Iyer SP. Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between India and the United States. JCO Glob Oncol. 2020, 6:1124-33. 10.1200\/GO.20.00012","journal-title":"JCO Glob Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers KA","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN, et al.. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica. 2021, 106:2364-73. 10.3324\/haematol.2020.272500","journal-title":"Haematologica"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015493","article-title":"Zanubrutinib is well tolerated and effective in patients with CLL\/SLL intolerant of ibrutinib\/acalabrutinib: updated results","volume":"9","author":"Shadman M","year":"2025","unstructured":"Shadman M, Burke JM, Cultrera J, et al.. Zanubrutinib is well tolerated and effective in patients with CLL\/SLL intolerant of ibrutinib\/acalabrutinib: updated results. Blood Adv. 2025, 9:4100-10. 10.1182\/bloodadvances.2024015493","journal-title":"Blood Adv"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002759","article-title":"The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana and the path to universal health coverage in India: Overcoming the challenges of stewardship and governance","volume":"16","author":"Angell BJ","year":"2019","unstructured":"Angell BJ, Prinja S, Gupt A, Jha V, Jan S. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana and the path to universal health coverage in India: Overcoming the challenges of stewardship and governance. PLoS Med. 2019, 16:1002759. 10.1371\/journal.pmed.1002759","journal-title":"PLoS Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01482-6","article-title":"Chronic lymphocytic leukemia: time-limited therapy in the first-line setting and role of minimal residual disease","volume":"26","author":"Stumpf J","year":"2024","unstructured":"Stumpf J, Al-Sawaf O. Chronic lymphocytic leukemia: time-limited therapy in the first-line setting and role of minimal residual disease. Curr Oncol Rep. 2024, 26:136-46. 10.1007\/s11912-023-01482-6","journal-title":"Curr Oncol Rep"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104243","article-title":"Efficacy and challenges involving combination therapies in CLL","volume":"29","author":"Alanazi MA","year":"2024","unstructured":"Alanazi MA, Kwa FA, Omar MM, Antonipillai J, Jackson DE. Efficacy and challenges involving combination therapies in CLL. Drug Discov Today. 2024, 29:104243. 10.1016\/j.drudis.2024.104243","journal-title":"Drug Discov Today"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/446890-patterns-of-brutons-tyrosine-kinase-inhibitor-btki-usage-in-b-cell-lymphomas-in-india-a-questionnaire-based-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T03:54:11Z","timestamp":1766375651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/446890-patterns-of-brutons-tyrosine-kinase-inhibitor-btki-usage-in-b-cell-lymphomas-in-india-a-questionnaire-based-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.99794","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,21]]}}}